Siegfried DINAMIQS Granted Swissmedic License for Viral Vector Production

DINAMIQS, a subsidiary of Siegfried AG, has obtained a Swissmedic license for cGMP viral vector manufacturing. This milestone allows DINAMIQS to produce and release genomic medicines under stringent conditions. Positioned as a fully integrated Contract Development and Manufacturing Organization (CDMO), DINAMIQS now offers comprehensive services from process development to manufacturing.

The Swissmedic approval is a crucial step in DINAMIQS's growth and positions Siegfried more prominently in the advanced therapy market. The Zurich facility, spanning 2,500 m², facilitates viral vector production at scales up to 1,000L, streamlining processes for global compliance. This license enhances DINAMIQS's ability to partner with gene therapy innovators globally, enabling quicker and more efficient paths to market.